Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2016

View Archived Issues

Novel small molecule selected for clinical development to treat spinal muscular atrophy

BGP-15 improves ventilation-induced diaphragm dysfunction in preclinical model

Takeda Pharmaceutical reports MGAT2 inhibitors

Merck & Co. patents potassium channel blockers

Inhibition of RIPK1 kinase as axonal protective strategy in human degenerative disease

LOX-1 is a specific marker of human PMN-MDSCs in cancer patients

Novel DNA vaccines provide enhanced protection from Pseudomonas aeruginosa in mice

Navigen receives SBIR award to support the development of its anti-RSV compound

UPCI announces NCI grants for early detection of cancer

AdAlta raises AUD 10 million to accelerate new therapies for lung fibrosis

FDA grants orphan drug designation to dusquetide

Keystone's ceramide is given FDA orphan drug designation

Aurinia reports promising findings from phase IIb study of voclosporin in active lupus nephritis

Aveo Oncology initiates phase I/II trial of tivozanib

Novadigm Therapeutics discloses positive data from phase IIa trial

Bristol-Myers Squibb initiates phase I trial of BMS-986166 in healthy volunteers

Sanofi announces public dengue immunization program in Brazil with Dengvaxia

Zimmer Biomet announces acquisition of CD Diagnostics

Bavarian Nordic signs drug supply agreement with Bristol-Myers Squibb for the supply of Opdivo

Celsion reports updated results on its HEAT phase III trial

Vertex updates status of phase III program of VX-661 with ivacaftor for cystic fibrosis

AcelRx's phase III trial of ARX-04 in emergency room patients meets primary endpoint

AstraZeneca and Leo Pharma complete tralokinumab licensing agreement

Six-month update on Repros' study of enclomiphene in obese secondary hypogonadal men

FDA accepts Checkpoint Therapeutics' IND for CK-101